ArticleFrontiers in immunology2025

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.

Laura M Moser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.